Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) EPS (Weighted Average and Diluted): 2014-2024

Historic EPS (Weighted Average and Diluted) for Altimmune (ALT) over the last 8 years, with Dec 2024 value amounting to -$1.34.

  • Altimmune's EPS (Weighted Average and Diluted) rose 34.38% to -$0.21 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.07, marking a year-over-year increase of 31.85%. This contributed to the annual value of -$1.34 for FY2024, which is 19.28% up from last year.
  • Per Altimmune's latest filing, its EPS (Weighted Average and Diluted) stood at -$1.34 for FY2024, which was up 19.28% from -$1.66 recorded in FY2023.
  • Over the past 5 years, Altimmune's EPS (Weighted Average and Diluted) peaked at -$1.34 during FY2024, and registered a low of -$2.35 during FY2021.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$1.60, with a median of -$1.66 in 2023.
  • As far as peak fluctuations go, Altimmune's EPS (Weighted Average and Diluted) dropped by 23.04% in 2021, and later increased by 22.98% in 2022.
  • Altimmune's EPS (Weighted Average and Diluted) (Yearly) stood at -$1.91 in 2020, then fell by 23.04% to -$2.35 in 2021, then increased by 22.98% to -$1.81 in 2022, then climbed by 8.29% to -$1.66 in 2023, then climbed by 19.28% to -$1.34 in 2024.